Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859 · clinicaltrials.gov ↗

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Triple Negative
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Invasive

Sponsor

Emory University

Collaborators

[object Object]